Skye Bioscience, a biotechnology company focused on developing novel drugs that modulate the endocannabinoid system, has secured $50 million in private placement equity funding from co-led investors, Piper Sandler and Oppenheimer & Co. The investors were advised by a Paul Hastings team led by partners Seo Salimi and Will Magioncalda.
Biotech & Pharmaceuticals
January 30, 2024, 10:59 AM